JP2023527410A5 - - Google Patents
Info
- Publication number
- JP2023527410A5 JP2023527410A5 JP2022573201A JP2022573201A JP2023527410A5 JP 2023527410 A5 JP2023527410 A5 JP 2023527410A5 JP 2022573201 A JP2022573201 A JP 2022573201A JP 2022573201 A JP2022573201 A JP 2022573201A JP 2023527410 A5 JP2023527410 A5 JP 2023527410A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- macrophages
- bone marrow
- vsig4
- marrow cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063032337P | 2020-05-29 | 2020-05-29 | |
| US63/032,337 | 2020-05-29 | ||
| PCT/US2021/034784 WO2021243169A1 (en) | 2020-05-29 | 2021-05-28 | Anti-vsig4 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023527410A JP2023527410A (ja) | 2023-06-28 |
| JP2023527410A5 true JP2023527410A5 (enExample) | 2024-06-05 |
Family
ID=78722851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022573201A Pending JP2023527410A (ja) | 2020-05-29 | 2021-05-28 | 骨髄細胞炎症性表現型を調節するための抗ｖｓｉｇ４組成物及び方法、ならびにその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230348603A1 (enExample) |
| EP (1) | EP4157886A4 (enExample) |
| JP (1) | JP2023527410A (enExample) |
| KR (1) | KR20230017778A (enExample) |
| CN (1) | CN115996953A (enExample) |
| AU (1) | AU2021281356A1 (enExample) |
| BR (1) | BR112022023892A2 (enExample) |
| CA (1) | CA3182814A1 (enExample) |
| IL (1) | IL298545A (enExample) |
| TW (1) | TW202210523A (enExample) |
| WO (1) | WO2021243169A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240392037A1 (en) * | 2022-01-10 | 2024-11-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Molecules that bind to neutrophil elastase polypeptides |
| KR20240058017A (ko) * | 2022-10-21 | 2024-05-03 | 주식회사 유틸렉스 | 항-vsig4 항체를 포함하는 항암용 조성물 |
| CN116380755B (zh) * | 2023-03-20 | 2023-11-21 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒 |
| JP2025027841A (ja) * | 2023-08-17 | 2025-02-28 | 国立大学法人 東京大学 | ＶＳＩＧ４とＳｉｇｌｅｃ－７との分子間相互作用に対する抗ＶＳＩＧ４、抗Ｓｉｇｌｅｃ－７阻害抗体 |
| KR20250062590A (ko) * | 2023-10-31 | 2025-05-08 | 인제대학교 산학협력단 | 신장 이식 후 만성거부반응 진단용 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008130204A1 (en) * | 2007-04-24 | 2008-10-30 | Eucell Bio Co., Ltd. | New anti-irc85 monoclonal antibody; and composition comprising the same for preventing and treating tuberculosis or enteritis disease; and the use thereof |
| AU2009319864A1 (en) * | 2008-11-25 | 2011-07-14 | Biogen Idec Ma Inc. | Use of DR6 and P75 antagonists to promote survival of cells of the nervous system |
| CN102459335B (zh) * | 2009-04-17 | 2015-11-25 | 伊缪纳斯制药株式会社 | 特异性结合Aβ寡聚体的抗体及其用途 |
| KR101730868B1 (ko) * | 2013-09-13 | 2017-04-27 | 인제대학교 산학협력단 | Ｖｓｉｇ４ 억제제를 유효성분으로 포함하는 난소암 예방 또는 치료용 약학조성물 |
| CN105924515B (zh) * | 2016-04-25 | 2019-06-14 | 中国人民解放军第三军医大学 | 免疫共刺激分子vsig4激活性表位肽、单克隆抗体及其制备方法和应用 |
| CN110944666B (zh) * | 2017-06-26 | 2024-12-31 | 博奥泰克尼公司 | 杂交瘤克隆、vsig-4的单克隆抗体，以及制备和使用的方法 |
| MX2021003673A (es) * | 2018-09-28 | 2021-09-23 | Eutilex Co Ltd | Anticuerpos anti-vsig4 humano y usos de los mismos. |
-
2021
- 2021-05-28 AU AU2021281356A patent/AU2021281356A1/en active Pending
- 2021-05-28 CA CA3182814A patent/CA3182814A1/en active Pending
- 2021-05-28 CN CN202180039150.1A patent/CN115996953A/zh active Pending
- 2021-05-28 TW TW110119507A patent/TW202210523A/zh unknown
- 2021-05-28 IL IL298545A patent/IL298545A/en unknown
- 2021-05-28 JP JP2022573201A patent/JP2023527410A/ja active Pending
- 2021-05-28 EP EP21814040.8A patent/EP4157886A4/en active Pending
- 2021-05-28 BR BR112022023892A patent/BR112022023892A2/pt not_active Application Discontinuation
- 2021-05-28 WO PCT/US2021/034784 patent/WO2021243169A1/en not_active Ceased
- 2021-05-28 KR KR1020227041080A patent/KR20230017778A/ko active Pending
- 2021-05-28 US US17/999,503 patent/US20230348603A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023527410A5 (enExample) | ||
| JP2021529753A5 (enExample) | ||
| JP2022535550A5 (enExample) | ||
| US20240182564A1 (en) | Treating cancer by blocking the interaction of tim-3 and its ligand | |
| JP2022535417A5 (enExample) | ||
| JP7618950B2 (ja) | 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物 | |
| US20220169694A1 (en) | Chimeric antigen receptor t cell therapy | |
| CN112703012A (zh) | 治疗癌症的方法 | |
| JP2022540768A5 (enExample) | ||
| JP6944925B2 (ja) | 組織浸潤ｎｋ細胞を検出する方法 | |
| EP4147053B1 (en) | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy | |
| US11648307B2 (en) | Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy | |
| JP2021500336A (ja) | 抗ｃｄ４７及び抗ｐｄ−ｌ１による卵巣癌の処置 | |
| US20250313855A1 (en) | Chimeric antigen receptor t cell therapy | |
| JP2022539038A5 (enExample) | ||
| JP2023501487A (ja) | 白血球上での細胞表面マーカーの発現を制御するための抗Ｃｌｅｖｅｒ－１剤、および抗Ｃｌｅｖｅｒ－１に基づくがん治療を導くためのこれらの使用 | |
| EP3388073A1 (en) | Targeting mesothelin in brain cancer | |
| EP4384276A1 (en) | Biomarkers for cd40 agonist therapy | |
| WO2025064690A1 (en) | High affinity antibodies recognizing core 2 o-glycans of variant muc5ac antigen, compositions containing and uses thereof | |
| JP2026510915A (ja) | 免疫療法の有効性に対する腫瘍微小環境の影響 |